Absorbable Powder Haemostat Use in Minimally Invasive Thoracic Surgery

Area of Science:

• Thoracic Surgery
• Surgical Hemostasis
• Oncology

Background:

• Intraoperative and postoperative bleeding are rare but serious risks in lung resection.
• Microporous Polysaccharide Haemospheres (ARISTA™AH) offer efficient hemostasis with a good safety profile in other surgical fields.
• The study aimed to assess ARISTA™AH's impact on thoracic surgery outcomes.

Purpose of the Study:

• Evaluate the efficacy of ARISTA™AH in managing bleeding during lung resection.
• Assess the impact of ARISTA™AH on short-term postoperative outcomes.
• Compare ARISTA™AH with other hemostatic agents used in thoracic surgery.

Main Methods:

• Retrospective analysis of a prospectively collected database of early-stage lung cancer patients.
• Propensity score matching to compare outcomes between ARISTA™AH and other hemostatic agents.
• Inclusion of patients undergoing VATS or RATS, excluding specific complex cases.

Main Results:

• ARISTA™AH use was associated with a significant reduction in total drain volume.
• No postoperative bleeding, blood transfusions, or 30-day mortality were observed in the ARISTA™AH group.
• ARISTA™AH significantly reduced the odds of postoperative complications, transfusion needs, and redo surgery.

Conclusions:

• Microporous Polysaccharide Haemospheres (ARISTA™AH) are a safe and effective hemostatic device for thoracic surgery.
• ARISTA™AH positively influences short-term postoperative outcomes in lung cancer patients.
• The findings support the use of ARISTA™AH to improve patient recovery after lung resection.